Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

478 RIBAVIRIN
(2006): Avila MP+, Arq Bras Oftalmol 69(2), 255 (with peginterferon)
Retinopathy
(2006): Andrade RJ+, Antivir Ther 11(4), 491 (15%) (with peginterferon)
(2006): Avila MP+, Arq Bras Oftalmol 69(2), 255 (with peginterferon)
(2006): Okuse C+, World J Gastroenterol 12(23), 3756 (5 cases)
(with peg-interferon)
Vision blurred
(2004): Bagheri H+, Pharmacotherapy 24(11), 1546 (with PEGinterferon
alfa-2b)
Other
Cough
(2001): Karim A+, Am J Med Sci 322(4), 233
Death
(2006): Helbling B+, JViralHepat13(11), 762 (2 cases) (with
peg-interferon)
Fever
(2002): Wirth S+, Hepatology 36(5), 1280 (with interferon)
Hepatotoxicity
(2006): Chaves J+, Clin Infect Dis 42(8), e72
Injection-site reactions
(2004): Bagheri H+, Pharmacotherapy 24(11), 1546 (with PEGinterferon
alfa-2b)
Myalgia/Myositis/Myopathy/Myotoxicity (>10%)
Nephrotoxicity
(2006): Alves Couto C+, Liver Int 26(10), 1294 (with peginterferon)
(2002): Willson RA, J Clin Gastroenterol 35(1), 89 (with interferon
alfa)
Vogt–Koyanagi–Harada disease
(2003): Sylvestre DL+, JViralHepat10(6), 467
RIBOFLAVIN
Synonyms: Lactoflavin; Vitamin B 2 ; Vitamin G
Trade name: Riobin
Indications: Riboflavin deficiency
Category: Vitamin
Half-life: 66–84 minutes
Reactions
Skin
Acne
Allergic reactions (sic)
Angioedema
Ichthyosis
(1985): Spirov G+, Dermatol Venereol (Sofia) 24, 50
Urticaria
Other
Anaphylactoid reactions/Anaphylaxis
(2001): Ou LS+, Ann Allergy Asthma Immunol 87(5), 430
RIFABUTIN
Trade name: Mycobutin (Pfizer)
Indications: Prevention of disseminated Mycobacterium avium
infection
Category: Antibiotic, rifamycin
Half-life: 45 hours
Clinically important, potentially hazardous interactions
with: amiodarone, anisindione, anticoagulants, azithromycin,
corticosteroids, cyclosporine, dapsone, delavirdine, dicumarol,
fosamprenavir, lapatinib, midazolam, oral contraceptives,
ritonavir, solifenacin, tacrolimus, temsirolimus, voriconazole
Reactions
Skin
Lupus erythematosus
(1997): Berning SE+, Lancet 349, 1521
Pigmentation
(1995): Smith JF+, Clin Infect Dis 21, 1515
(1990): Siegal FP+, AIDS 4(5), 433
Rash (sic) (11%)
Urticaria
Mucosal
Aphthous stomatitis
(1990): Siegal FP+, AIDS 4(5), 433
Eyes
Corneal opacity
(2002): Ponjavic V+, Acta Ophthalmol Scand 80(5), 553
Macular edema
(2002): Vaudaux JD+, J Antimicrob Chemother 49(2), 421
Ocular toxicity
(2006): Boyer SP+, Optometry 77(10), 494
(1997): Le Saux N+, Pediatr Infect Dis J 16(7), 716
Uveitis
(2005): Cano Parra J+, Arch Soc Esp Oftalmol 80(3), 137
(2005): Olesen HH+, Pediatr Infect Dis J 24(11), 1023
(2005): Skolik S+, Ocul Immunol Inflamm 13(6), 483
(2004): Mulliez P+, Rev Mal Respir 21(5 Pt 1), 1004
(2001): Bhagat N+, Ophthalmology 108(4), 750
(2000): Khan MA+, Eye 14 (Pt 3A), 344
(1999): Schaller UC+, Ophthalmologe 96(4), 267
(1998): Johnson TM+, J Pediatr Ophthalmol Strabismus 35(2), 119
(1998): Moorthy RS+, Surv Ophthalmol 42(6), 557
(1998): Ramon PM+, Rev Mal Respir 15(2), 204
(1997): Arevalo JF+, Ophthalmic Surg Lasers 28(4), 321
(1997): Saran BR, Ann Pharmacother 31(11), 1405
(1996): Diemer PR+, Klin Monatsbl Augenheilkd 209(1), 40
(1996): Nichols CW, Clin Infect Dis 22 Suppl 1, S43
(1996): Petrowski JT, J Am Optom Assoc 67(11), 693
(1996): Schimkat M+, Ger J Ophthalmol 5(4), 195
(1996): Zenone T+, Scand J Infect Dis 28(3), 325
(1995): Chevalley GF+, Klin Monatsbl Augenheilkd 206(5), 388
(1995): Dunn AM+, Pediatr Infect Dis J 14(3), 246
(1995): Frau E+, JFrOphtalmol18(6–7), 435
(1995): Gioulekas J+, Aust N Z J Ophthalmol 23(4), 319
(1995): Rifai A+, Arch Ophthalmol 113(6), 707
(1995): Tseng AL+, Ann Pharmacother 29(11), 1149
(1994): MMWR Morb Mortal Wkly Rep 43(35), 658
(1994): Havlir D+, Ann Intern Med 1994 Oct 1 121(7), 510
(1994): Jacobs DS+, Am J Ophthalmol 118(6), 716
(1994): Saran BR+, Arch Ophthalmol 112(9), 1159
(1990): Siegal FP+, AIDS 4(5), 433
Visual disturbances
(2002): Ponjavic V+, Acta Ophthalmol Scand 80(5), 553
(1996): Chaknis MJ+, Am J Ophthalmol 122(4), 580